2022---eli-lilly-and-company--goldman-sachs-maintains-its-neutral-opinion <2025-2027>

Eli Lilly's 2022 performance was characterized by several key milestones:

In a year marked by significant shifts in the pharmaceutical landscape, reaffirmed its Neutral rating on Eli Lilly and Company (LLY) during 2022. While the drugmaker demonstrated robust growth potential driven by its late-stage pipeline, analysts at the investment bank remained cautious regarding the stock’s valuation and broader macroeconomic headwinds. The 2022 Backdrop: Growth vs. Valuation Eli Lilly's 2022 performance was characterized by several

The maintenance of the Neutral stance did little to dampen investor enthusiasm in the long term. While the rating suggested a lack of immediate "buy" urgency from the bank's perspective, Eli Lilly finished 2022 as one of the best-performing large-cap pharmaceutical companies, setting the stage for its continued ascent in the years that followed. Eli Lilly's 2022 performance was characterized by several